Search Results

You are looking at 81 - 90 of 95 items for :

  • Refine by Access: Content accessible to me x
Clear All
Journal of Psychedelic Studies
Authors:
Avery Sapoznikow
,
Zachary Walsh
,
Kenneth W. Tupper
,
Earth Erowid
, and
Fire Erowid

. S. , & Brewerton , T. D. ( 2016 ). Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA . The Lancet Psychiatry, 3 ( 5 ), 481 – 488 . doi: 10.1016/S2215-0366(15)00576-3 10.1016/S2215

Open access

Introduction: pharmacovigilance beyond the individual level? In December 2023 the Multidisciplinary Association for Psychedelic Studies submitted a new drug application to the Food & Drug Administration for the use of MDMA in the treatment of post

Open access

-B [2,5-dimethoxy-4-bromophenethylamine] etc.), 5-MeO-DMT (5-methoxy- N,N -dimethyltryptamine), Ayahuasca (or analogues), smoked DMT ( N,N -Dimethyltryptamine), LSD (Lysergic acid diethylamide), MDMA (3,4-Methylenedioxy-methamphetamine), Mescaline

Open access

among MDMA and other drug users . Drug and Alcohol Dependence , 96 ( 1–2 ), 99 – 110 . 10.1016/j.drugalcdep.2008.02.003 Han , X. , Wu , X. , Wang , Y. , Sun , Y. , Ding , W. , Cao , M. , ( 2018 ). Alterations of resting-state static and

Open access
Journal of Behavioral Addictions
Authors:
Maria Picó-Pérez
,
Víctor Costumero
,
Juan Verdejo-Román
,
Natalia Albein-Urios
,
José Miguel Martínez-González
,
Carles Soriano-Mas
,
Alfonso Barrós-Loscertales
, and
Antonio Verdejo-Garcia

. ( 2005 ). Differential effects of MDMA, cocaine, and cannabis use severity on distinctive components of the executive functions in polysubstance users: A multiple regression analysis . Addictive Behaviors , 30 ( 1

Open access

, psilocybin, MDMA, and ketamine . The Journal of Neuroscience , 41 ( 5 ), 891 – 900 . https://doi.org/10.1523/jneurosci.1659-20.2020 . 10.1523/JNEUROSCI.1659

Open access
Journal of Psychedelic Studies
Authors:
Eduardo Ekman Schenberg
,
Maria Angélica de Castro Comis
,
João Felipe Morel Alexandre
,
Bruno Daniel Rasmussen Chaves
,
Luís Fernando Tófoli
, and
Dartiu Xavier da Silveira

mentioned by some patients included “acid” (LSD), “ecstasy” (MDMA), mushrooms, solvents/inhalants, and amphetamines. Only one patient had previous experience with opioids. All participants were white and all but one were Brazilians. Twenty participants (91

Open access
Journal of Psychedelic Studies
Authors:
Eduardo Ekman Schenberg
,
Maria Angélica de Castro Comis
,
João Felipe Morel Alexandre
,
Luís Fernando Tófoli
,
Bruno Daniel Rasmussen Chaves
, and
Dartiu Xavier da Silveira

for one patient each. Other substances mentioned by some patients included “acid” [lysergic acid diethylamide (LSD)], “ecstasy” [3,4-methylenedioxymethamphetamine (MDMA)], mushrooms, solvents/inhalants, and amphetamines. Only one patient had previous

Open access

-being or mental health. Accordingly, the following types of research were excluded: reviews or other non-empirical work, purely qualitative studies, studies on other psychoactive substances such as ketamine, cannabis or MDMA, studies on microdosing, studies

Open access

to rate how often their use of each of 12 drug categories (alcohol, tobacco, cannabis, MDMA, amphetamines, cocaine, opiates, classic psychedelics, inhalants, sedatives/hypnotics, dissociatives, atypical psychedelics) is motivated by entheogenic

Open access